Macclesfield, United Kingdom

Jason Grant Kettle

This inventor holds 33 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Cancer Treatment Compounds. Top assignees: Astrazeneca Ab, Dizal (Jiangsu) Pharmaceutical Co., Ltd., Zeneca Limited. Active years: 2001-2026.

USPTO Granted Patents = 33 

% Patents Active = 63.6

 

 

Average Co-Inventor Count = 3.8

ph-index = 7

Forward Citations = 184(Granted Patents)


Location History:

  • Macklesfield, GB (2006)
  • Cheshire, GB (2013)
  • Macclesfield, GB (2001 - 2022)
  • Cambridge, GB (2019 - 2024)

Company Filing History:


Years Active: 2001-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
HPK1 Inhibitors
Triazolopyrimidine Compounds
Anticancer Agents
JAK1 Selective Inhibitors
Phenoxyquinazoline Compounds
C-anilinoquinazoline Compounds
Pyrimidine Derivatives
Indole Derivatives
MCP-1 Antagonists
Bicyclic Pyrrole Derivatives
Antiproliferative Agents
Chemical Compounds
33 patents (USPTO):Explore Patents

Title: Jason Grant Kettle: Innovator in Cancer Treatment

Introduction

Jason Grant Kettle is a prolific inventor based in Macclesfield, GB, known for his significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 29 patents, Kettle has played a pivotal role in advancing cancer treatment methodologies. His work focuses primarily on novel compounds that have the potential to combat cell proliferative disorders effectively.

Latest Patents

Among his latest patents are innovations related to triazolopyrimidine compounds, specifically their applications in treating cancer. Kettle's inventive process encompasses compounds of Formula (I) and further includes tetracyclic heteroaryl compounds and their pharmaceutically acceptable salts. The specifications extend to various processes and intermediates required for their preparation, as well as the pharmaceutical compositions developed from these compounds, aiming to enhance treatment options for patients suffering from similar ailments.

Career Highlights

Throughout his career, Jason Grant Kettle has been associated with leading pharmaceutical companies, including AstraZeneca AB and Dizal (Jiangsu) Pharmaceutical Co., Ltd. His tenure in these organizations has allowed him to further his research and development efforts in pharmaceutical innovation, particularly in the area of oncology.

Collaborations

Kettle has collaborated with notable colleagues such as Alan Wellington Faull and Andrew John Barker. These partnerships are testament to the intricate work involved in developing new therapeutic solutions and highlight the importance of teamwork in scientific advancement.

Conclusion

Jason Grant Kettle's extensive patent portfolio and his ongoing contributions to pharmaceutical research underline his status as a key innovator in the fight against cancer. His commitment to discovering novel therapeutic compounds not only showcases his ingenuity but also represents a significant impact on the medical community, offering hope to countless patients worldwide.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…